RE:RE:RE:RE:BOJO Interview For CURA if they pass or do not pass SAFE in NDAA its a win. The longer they prolong it the more CURA can capitalize and grow, its the small cannabis players that are being held back and hurt the most. Banking + 280E with uplisting = Incredible success for MSO Q2 next year. CURA is on a trejectory path in the EU most can-not comprehend. Our CBD products are going to be launched in the EU in 2022, THC should be late 2022 or 2023 for adult use, the medical is going to see massive growth in Germany UK Italy Spain Portugal next year. NEW Select products to be launched in America, and New financing is going to be Huge savings$$. Keep Spending BoJo!! Grow CURA into the Gorilla it is!!